Terms: = Ovarian cancer AND BCL3, P20749, 602, ENSG00000069399, D19S37, BCL4 AND Treatment
24 results:
1. Hospital Volume and Quality of Care for Emergency Gynecologic Care.
Kalinowska V; Huang Y; Buckley A; St Clair CM; Pua T; Khoury-Collado F; Hou JY; Hershman DL; Wright JD
Obstet Gynecol; 2024 Feb; 143(2):303-311. PubMed ID: 38086058
[TBL] [Abstract] [Full Text] [Related]
2. A cross-sectional study on Chinese oncology nurses' knowledge of bone health among cancer patients.
Shan J; Lv S; Chen L; Li T; Li J; Wang S; Zhang C
Support Care Cancer; 2023 Aug; 31(8):501. PubMed ID: 37526757
[TBL] [Abstract] [Full Text] [Related]
3. Germline Genetic Testing After cancer Diagnosis.
Kurian AW; Abrahamse P; Furgal A; Ward KC; Hamilton AS; Hodan R; Tocco R; Liu L; Berek JS; Hoang L; Yussuf A; Susswein L; Esplin ED; Slavin TP; Gomez SL; Hofer TP; Katz SJ
JAMA; 2023 Jul; 330(1):43-51. PubMed ID: 37276540
[TBL] [Abstract] [Full Text] [Related]
4. Meta-Analysis of Survival Effects of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1).
Jeong SY; Lee KJ; Cha J; Park SY; Kim HS; Kim JH; Lee JJ; Kim N; Park ST
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557069
[TBL] [Abstract] [Full Text] [Related]
5. Reproductive Outcomes in Young Breast cancer Survivors Treated (15-39) in Ontario, Canada.
Rushton M; Pudwell J; Wei X; Powell M; Richardson H; Velez MP
Curr Oncol; 2022 Nov; 29(11):8591-8599. PubMed ID: 36421330
[TBL] [Abstract] [Full Text] [Related]
6. PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine.
Baldelli E; Hodge KA; Bellezza G; Shah NJ; Gambara G; Sidoni A; Mandarano M; Ruhunusiri C; Dunetz B; Abu-Khalaf M; Wulfkuhle J; Gallagher RI; Liotta L; de Bono J; Mehra N; Riisnaes R; Ravaggi A; Odicino F; Sereni MI; Blackburn M; Zupa A; Improta G; Demsko P; Crino' L; Ludovini V; Giaccone G; Petricoin EF; Pierobon M
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34620701
[TBL] [Abstract] [Full Text] [Related]
7. Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer.
Leung JH; Lang HC; Wang SY; Lo HF; Chan AL
Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):489-496. PubMed ID: 34241562
[TBL] [Abstract] [Full Text] [Related]
8. The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker.
Klotz DM; Link T; Goeckenjan M; Wimberger P; Kuhlmann JD
Mol Oncol; 2021 Sep; 15(9):2491-2503. PubMed ID: 33690968
[TBL] [Abstract] [Full Text] [Related]
9. Risks of Second Primary Gynecologic cancers following ovarian cancer treatment in Asian Ethnic Subgroups in the United States, 2000-2016.
Mukand NH; Zolekar A; Ko NY; Calip GS
Cancer Epidemiol Biomarkers Prev; 2020 Nov; 29(11):2220-2229. PubMed ID: 32856609
[TBL] [Abstract] [Full Text] [Related]
10. Interval debulking surgery is not worth the wait: a National cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
[TBL] [Abstract] [Full Text] [Related]
11. Adjuvant vaginal brachytherapy and chemotherapy versus pelvic radiotherapy in early-stage endometrial cancer: Outcomes by risk factors.
Tatebe K; Hasan Y; Son CH
Gynecol Oncol; 2019 Dec; 155(3):429-435. PubMed ID: 31610885
[TBL] [Abstract] [Full Text] [Related]
12. ovarian response and follow-up outcomes in women diagnosed with cancer having fertility preservation: Comparison of random start and early follicular phase stimulation - cohort study.
Muteshi C; Child T; Ohuma E; Fatum M
Eur J Obstet Gynecol Reprod Biol; 2018 Nov; 230():10-14. PubMed ID: 30227359
[TBL] [Abstract] [Full Text] [Related]
13. ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers.
Derks-Smeets IAP; Schrijver LH; de Die-Smulders CEM; Tjan-Heijnen VCG; van Golde RJT; Smits LJ; Caanen B; van Asperen CJ; Ausems M; Collée M; van Engelen K; Kets CM; van der Kolk L; Oosterwijk JC; van Os TAM; ; Rookus MA; van Leeuwen FE; Gómez García EB
Br J Cancer; 2018 May; 119(3):357-363. PubMed ID: 29937543
[TBL] [Abstract] [Full Text] [Related]
14. Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy.
Yoon TI; Hwang UK; Kim ET; Lee S; Sohn G; Ko BS; Lee JW; Son BH; Kim S; Ahn SH; Kim HJ
Breast Cancer Res Treat; 2017 Sep; 165(2):311-320. PubMed ID: 28601930
[TBL] [Abstract] [Full Text] [Related]
15. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
[TBL] [Abstract] [Full Text] [Related]
16. Predicting ovarian Activity in Women Affected by Early Breast cancer: A Meta-Analysis-Based Nomogram.
Barnabei A; Strigari L; Marchetti P; Sini V; De Vecchis L; Corsello SM; Torino F
Oncologist; 2015 Oct; 20(10):1111-8. PubMed ID: 26341758
[TBL] [Abstract] [Full Text] [Related]
17. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer.
Chudecka-Głaz AM; Cymbaluk-Płoska AA; Menkiszak JL; Sompolska-Rzechuła AM; Tołoczko-Grabarek AI; Rzepka-Górska IA
J Ovarian Res; 2014; 7():62. PubMed ID: 25018782
[TBL] [Abstract] [Full Text] [Related]
18. Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis.
Vay A; Kumar S; Seward S; Semaan A; Schiffer CA; Munkarah AR; Morris RT
Gynecol Oncol; 2011 Dec; 123(3):456-60. PubMed ID: 21855120
[TBL] [Abstract] [Full Text] [Related]
19. Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.
Choi CH; Lee YY; Song TJ; Park HS; Kim MK; Kim TJ; Lee JW; Lee JH; Bae DS; Kim BG
Cancer; 2011 May; 117(10):2104-11. PubMed ID: 21523722
[TBL] [Abstract] [Full Text] [Related]
20. GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro.
Bellyei S; Schally AV; Zarandi M; Varga JL; Vidaurre I; Pozsgai E
Cancer Lett; 2010 Jul; 293(1):31-40. PubMed ID: 20064686
[TBL] [Abstract] [Full Text] [Related]
[Next]
